InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-56.4%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Saik Andrew, Chief Financial Officer. Officer active across 3 companies, notably VYNE Therapeutics Inc.. Aggregated, 20 reports have been published. Breakdown: 0 buy · 2 sells. Total volume traded: €37k. History available since 28 May 2021. The latest transaction was filed on 24 June 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations20 total
5,696 sharesCommon StockSEC:0001628280-26-045286:0
5,700 shares@ US$7.61100.0% of flowCommon StockSEC:0001655759-25-000109:0
59,600 shares0Common StockSEC:0001655759-25-000091:0
49,092 shares0Common StockSEC:0001655759-25-000027:0
61,409 shares0Common StockSEC:0001655759-24-000105:0
23,021 shares@ US$19.0079.2% of flowCommon StockSEC:0001104659-23-117093:0
908 shares@ US$10.808.6% of flowCommon StockSEC:0001104659-23-103508:0
908 shares@ US$11.741.9% of flowCommon StockSEC:0001104659-23-074233:0
909 shares@ US$14.192.3% of flowCommon StockSEC:0001104659-23-036043:0
14,700 shares0Common StockSEC:0001104659-23-008588:0
718 shares@ US$12.371.6% of flowCommon StockSEC:0001104659-23-000337:0
908 shares@ US$13.432.2% of flowCommon StockSEC:0001104659-22-129883:0
908 shares@ US$14.852.7% of flowCommon StockSEC:0001104659-22-102662:0
3,632 shares@ US$12.48100.0% of flowCommon StockSEC:0001104659-22-073886:0
10,300 shares0Common StockSEC:0001104659-22-009563:0
10,300 shares0Common StockSEC:0001104659-22-009563
52,156 shares0Common StockSEC:0001104659-21-084279
52,156 shares0Common StockSEC:0001104659-21-084279:0
3,017 shares@ US$3.35750.043% mcap50.0% of flowCommon StockSEC:0001209191-21-037193:0
3,017 shares@ US$3.357550.0% of flowCommon StockSEC:0001209191-21-037193
20 of 20 declarations
About Saik Andrew
Andrew Saik is the Chief Financial Officer and EVP at Vyne Therapeutics Inc. and Intercept Pharmaceuticals, Inc. He is responsible for financial management and strategy for the companies. His expertise in finance enables him to oversee financial operations and ensure transparency in financial reporting. He plays a key role in supporting the financial strategy of these firms.
